144822-82-2Relevant academic research and scientific papers
Imidazo ring PAR4 antagonist and medical applications thereof
-
Paragraph 0225; 0227; 0231, (2020/01/12)
The invention relates to an imidazo ring compound represented by formula (I) or formula (II), or a pharmaceutically acceptable salt or ester or solvate thereof. The compound disclosed by the inventioncan be used for preparing medicines for preventing or treating thromboembolic diseases.
Method for synthesizing tasimelteon key intermediate (1R, 2R)-2-(2,3-dihydrobenzofuran-4-yl) cyclopropanemethanol
-
Paragraph 0039; 0040; 0041; 0058-0060; 0080-0082, (2017/07/21)
The invention discloses a method for synthesizing a tasimelteon key intermediate (1R, 2R)-2-(2,3-dihydrobenzofuran-4-yl) cyclopropanemethanol. The method comprises the following steps: 1) taking 1,3-dimethoxybenzene, tetramethylethylenediamine and a solvent, and adding ethylene oxide for reacting under the alkali effect to obtain a compound 1; 2) performing acidifying and ring-closing on the compound 1 to obtain a compound 2; 3) dissolving the compound 2 in an organic solvent, and adding trifluoromethanesulfonic anhydride under the alkali effect to obtain a compound 3; 4) dissolving ethyl acrylate or methyl acrylate and the compound 3 in the organic solvent, and reacting with a ligand under the effects of an alkali reagent and a palladium catalyst to obtain a compound 4; 5) dissolving the compound 4 in the organic solvent, and adding a reducing reagent to obtain a compound 5; 6) dissolving the compound 5 in the organic solvent, adding zinc ethide, diiodomethane and a chiral ligand, carrying out an asymmetrical Simmons-Smith reaction, thereby obtaining the product. The method disclosed by the invention can achieve the effects of reducing synthesis steps, improving the synthetic overall linear yield and reducing the cost. The structural formula is as shown in the description.
Therapeutic diphenyl ether ligands
-
Page/Page column 37, (2010/10/20)
This invention is directed to compounds of formula Ia, Ib or Ic and to pharmaceutical compositions thereof: or a prodrug thereof and a pharmaceutically acceptable carrier, wherein the R groups are defined in the specification; and, in which the dashed line represents an optional double bond. The invention is also directed to methods of treating, diagnosing, and preventing disorders of the central nervous system that are associated with 5HT receptors, including obesity, attention deficit disorder, migraine, depression, epilepsy, anxiety, Alzheimer's disease, withdrawal from drug abuse, pain, schizophrenia, stress-related disorders, panic disorder, sleep disorders, phobias, obsessive compulsive disorder, post-traumatic-stress syndrome, immune system depression, stress-induced gastrointestinal dysfunction, stress-induced cardiovascular dysfunction, and sexual dysfunction.
Synthesis of substituted 2,3-dihydrobenzofuran in a process involving a facile acyl migration
Li, Wen-Sen,Guo, Zhenrong,Thornton, John,Katipally, Kishta,Polniaszek, Richard,Thottathil, John,Vu, Truc,Wong, Michael
, p. 1923 - 1925 (2007/10/03)
Reduction of 2,6-diacetoxy-2′-bromoacetophenone (10) with NaBH4 led to 3,4-diacetoxydihydrobenzofuran (12) in a process involving acyl migration followed by cyclization. Subsequent hydrogenolysis gave 4-acetoxydihydrobenzofuran which, upon saponification, afforded 4-hydroxydihydrobenzofuran (8) in good yield. This approach is shown to be a general method for preparation of substituted dihydrobenzofurans.
SUBSTITUTED UREA DERIVATIVES AS CELL ADHESION INHIBITORS
-
Example 71, (2010/01/30)
Compounds of formula (II) where R 1 is in the para or meta position and is (A); R 2 and R 3 are each independently selected from hydrogen, nitro, C 1-6 alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkoxyl, C 1-6 alkylamino, C 1-6 dialkylamino, C 1-6 akylC 1-4 alkoxyl, C 1-6 alkylaminoC 1-6 alkyl, amino, cyano, halogeno, trifluoromethyl, ?CO 2 R 12 and ?CONR 12 R 13 , where R 12 and R 13 are independently selected from hydrogen or C 1-6 alkyl, or R 2 and R 3 together with the phenyl to which they are attached form a 9 or 10 membered bicyclic ring system; R 4 is C 1-4 alkyl; R 5 is selected from hydrogen and C 1-4 alkyl; R 6 is selected from C 1-6 alkyl, C 1-4 alkyl(C 4-6 )cycloalkyl, C 1-6 alkyl(C 1-6 )alkoxyl, C 1-6 alkylS(C 1-6 )alkyl, C 1-4 alkylsulphonyl(C 1-4 )alkyl; (B) where q is an integer from 1 to 6 and R 14 is halogeno; R 7 is selected from C 1-6 alkyl, C 1-8 alkoxylcarbonyl, C 2-6 alkenyl, 1,3-benzodioxol-5-yl and aryl each optionally substituted by one or more substituents selected from C 1-4 alkoxy, C 1-6 alkyl, cyano, halogeno, and trifluoromethyl; R 8 is aryl, heteroaryl, a bicyclic heteroaryl ring system linked to the nitrogen via a ring carbon or a 9 or 10 membered bicyclic ring system linked to the nitrogen via a ring carbon and each ring is optionally substituted with up to two substituents, which may be the same or different, and are selected from C 1-6 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-6 alkylC 1-4 alkoxyl, C 1-6 alkylaminoC 1-6 alkyl, hydroxy, ?CO 2 H, ?(CH 2 ) p OH where p is 1 or 2, cyano, halogeno, and trifluoromethyl; R 9 and R 10 are each independently selected from hydrogen and C 1-4 alkyl or R 8 and R 9 together with the nitrogen to which they are attached form a dihydroindolyl, or a dihidroquinolinyl group; R 11 is selected from carboxyl, tetrazolyl, alkyl sulphonylcarbamyl, sulfo and sulfino; Y is oxygen, sulphur or sulfonyl; m is 0 or 1; and n is 0 or an integer from 1 to 4 with the proviso that when m and n cannot both be 0 and when m is 1, n is 0; or a pharmaceutically acceptable salt or in vivo hydrolyzable ester thereof. The compounds inhibit the interaction of vascular cell-adhesion molecule-1 and fibronectin with integrin very late antigen 4 (a 4 b 1 ). They have therapeutic applications such as in multiple sclerosis, rheumatoid arthritis, asthma, coronary artery disease and psoriasis
